Compare FOLD & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOLD | LAZ |
|---|---|---|
| Founded | 2002 | 1848 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.7B |
| IPO Year | 2006 | 2004 |
| Metric | FOLD | LAZ |
|---|---|---|
| Price | $14.49 | $41.82 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 8 |
| Target Price | $27.25 | ★ $52.75 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 4.21% |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ 0.91 |
| Revenue | N/A | ★ $3,186,466,000.00 |
| Revenue This Year | $20.50 | $13.36 |
| Revenue Next Year | $18.59 | $13.72 |
| P/E Ratio | ★ N/A | $51.98 |
| Revenue Growth | N/A | ★ 1.48 |
| 52 Week Low | $5.66 | $38.67 |
| 52 Week High | $14.50 | $58.75 |
| Indicator | FOLD | LAZ |
|---|---|---|
| Relative Strength Index (RSI) | 74.18 | 36.63 |
| Support Level | $14.21 | $38.84 |
| Resistance Level | N/A | $51.31 |
| Average True Range (ATR) | 0.02 | 2.37 |
| MACD | -0.00 | -0.50 |
| Stochastic Oscillator | 100.00 | 1.87 |
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Lazard Inc is a financial advisory and asset management firm with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Geographically, the company earns key revenue in the Americas, EMEA then Asia-Pacific.